BACKGROUND: Single-nucleotide polymorphisms (SNPs) within the regulatory β2 subunit of the voltage-gated calcium channel (CACNB2) may contribute to variable treatment response to antihypertensive drugs and adverse cardiovascular outcomes. METHODS AND RESULTS: SNPs in CACNB2 from 60 ethnically diverse individuals were identified and characterized. Three common SNPs (rs2357928, rs7069292, and rs61839258) and a genome-wide association study-identified intronic SNP (rs11014166) were genotyped for a clinical association study in 5598 hypertensive patients with coronary artery disease randomized to aβ-blocker (BB) or a calcium channel blocker (CCB) treatment strategy in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES). Reporter gene assays were conducted on the promoter SNP, showing association with clinical outcomes. Twenty-one novel SNPs were identified. A promoter A>G SNP (rs2357928) was found to have significant interaction with treatment strategy for adverse cardiovascular outcomes (P for interaction, 0.002). In whites, rs2357928 GG patients randomized to CCB were more likely to experience an adverse outcome than those randomized to BB treatment strategy, with adjusted hazard ratio (HR) (CCB versus BB) of 2.35 (95% CI, 1.19 to 4.66; P=0.014). There was no evidence for such treatment difference in AG (HR, 1.16; 95% CI, 0.75 to 1.79; P=0.69) and AA (HR, 0.63; 95% CI, 0.36 to 1.11; P=0.11) patients. This finding was consistent in Hispanics and blacks. CACNB2 rs11014166 showed similar pharmacogenetic effect in Hispanics, but not in whites or blacks. Reporter assay analysis of rs2357928 showed a significant increase in promoter activity for the G allele compared to the A allele. CONCLUSIONS: These data suggest that genetic variation within CACNB2 may influence treatment-related outcomes in high-risk patients with hypertension.
RCT Entities:
BACKGROUND: Single-nucleotide polymorphisms (SNPs) within the regulatory β2 subunit of the voltage-gated calcium channel (CACNB2) may contribute to variable treatment response to antihypertensive drugs and adverse cardiovascular outcomes. METHODS AND RESULTS: SNPs in CACNB2 from 60 ethnically diverse individuals were identified and characterized. Three common SNPs (rs2357928, rs7069292, and rs61839258) and a genome-wide association study-identified intronic SNP (rs11014166) were genotyped for a clinical association study in 5598 hypertensivepatients with coronary artery disease randomized to a β-blocker (BB) or a calcium channel blocker (CCB) treatment strategy in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES). Reporter gene assays were conducted on the promoter SNP, showing association with clinical outcomes. Twenty-one novel SNPs were identified. A promoter A>G SNP (rs2357928) was found to have significant interaction with treatment strategy for adverse cardiovascular outcomes (P for interaction, 0.002). In whites, rs2357928 GG patients randomized to CCB were more likely to experience an adverse outcome than those randomized to BB treatment strategy, with adjusted hazard ratio (HR) (CCB versus BB) of 2.35 (95% CI, 1.19 to 4.66; P=0.014). There was no evidence for such treatment difference in AG (HR, 1.16; 95% CI, 0.75 to 1.79; P=0.69) and AA (HR, 0.63; 95% CI, 0.36 to 1.11; P=0.11) patients. This finding was consistent in Hispanics and blacks. CACNB2rs11014166 showed similar pharmacogenetic effect in Hispanics, but not in whites or blacks. Reporter assay analysis of rs2357928 showed a significant increase in promoter activity for the G allele compared to the A allele. CONCLUSIONS: These data suggest that genetic variation within CACNB2 may influence treatment-related outcomes in high-risk patients with hypertension.
Authors: Jyothi Arikkath; Chien-Chang Chen; Christopher Ahern; Valérie Allamand; Jason D Flanagan; Roberto Coronado; Ronald G Gregg; Kevin P Campbell Journal: J Biol Chem Date: 2002-10-29 Impact factor: 5.157
Authors: Michael Brudno; Chuong B Do; Gregory M Cooper; Michael F Kim; Eugene Davydov; Eric D Green; Arend Sidow; Serafim Batzoglou Journal: Genome Res Date: 2003-03-12 Impact factor: 9.043
Authors: Carl J Pepine; Eileen M Handberg; Rhonda M Cooper-DeHoff; Ronald G Marks; Peter Kowey; Franz H Messerli; Giuseppe Mancia; José L Cangiano; David Garcia-Barreto; Matyas Keltai; Serap Erdine; Heather A Bristol; H Robert Kolb; George L Bakris; Jerome D Cohen; William W Parmley Journal: JAMA Date: 2003-12-03 Impact factor: 56.272
Authors: C J Pepine; E Handberg-Thurmond; R G Marks; M Conlon; R Cooper-DeHoff; P Volkers; P Zellig Journal: J Am Coll Cardiol Date: 1998-11 Impact factor: 24.094
Authors: Daniel Levy; Georg B Ehret; Kenneth Rice; Germaine C Verwoert; Lenore J Launer; Abbas Dehghan; Nicole L Glazer; Alanna C Morrison; Andrew D Johnson; Thor Aspelund; Yurii Aulchenko; Thomas Lumley; Anna Köttgen; Ramachandran S Vasan; Fernando Rivadeneira; Gudny Eiriksdottir; Xiuqing Guo; Dan E Arking; Gary F Mitchell; Francesco U S Mattace-Raso; Albert V Smith; Kent Taylor; Robert B Scharpf; Shih-Jen Hwang; Eric J G Sijbrands; Joshua Bis; Tamara B Harris; Santhi K Ganesh; Christopher J O'Donnell; Albert Hofman; Jerome I Rotter; Josef Coresh; Emelia J Benjamin; André G Uitterlinden; Gerardo Heiss; Caroline S Fox; Jacqueline C M Witteman; Eric Boerwinkle; Thomas J Wang; Vilmundur Gudnason; Martin G Larson; Aravinda Chakravarti; Bruce M Psaty; Cornelia M van Duijn Journal: Nat Genet Date: 2009-05-10 Impact factor: 38.330
Authors: Kelly A Frazer; Lior Pachter; Alexander Poliakov; Edward M Rubin; Inna Dubchak Journal: Nucleic Acids Res Date: 2004-07-01 Impact factor: 16.971
Authors: Elvin Tyrone Price; Michael A Pacanowski; Michael A Martin; Rhonda M Cooper-DeHoff; Carl J Pepine; Issam Zineh; Julie A Johnson Journal: Pharmacogenet Genomics Date: 2011-06 Impact factor: 2.089
Authors: J A Johnson; L H Cavallari; A L Beitelshees; J P Lewis; A R Shuldiner; D M Roden Journal: Clin Pharmacol Ther Date: 2011-09-14 Impact factor: 6.875
Authors: Dan M Roden; Julie A Johnson; Stephen E Kimmel; Ronald M Krauss; Marisa Wong Medina; Alan Shuldiner; Russell A Wilke Journal: Circ Res Date: 2011-09-16 Impact factor: 17.367
Authors: Lisa de Las Fuentes; Yun Ju Sung; Karen L Schwander; Sonia Kalathiveetil; Steven C Hunt; Donna K Arnett; D C Rao Journal: Front Genet Date: 2013-12-25 Impact factor: 4.599
Authors: Joshua C Bis; Colleen Sitlani; Ryan Irvin; Christy L Avery; Albert Vernon Smith; Fangui Sun; Daniel S Evans; Solomon K Musani; Xiaohui Li; Stella Trompet; Bouwe P Krijthe; Tamara B Harris; P Miguel Quibrera; Jennifer A Brody; Serkalem Demissie; Barry R Davis; Kerri L Wiggins; Gregory J Tranah; Leslie A Lange; Nona Sotoodehnia; David J Stott; Oscar H Franco; Lenore J Launer; Til Stürmer; Kent D Taylor; L Adrienne Cupples; John H Eckfeldt; Nicholas L Smith; Yongmei Liu; James G Wilson; Susan R Heckbert; Brendan M Buckley; M Arfan Ikram; Eric Boerwinkle; Yii-Der Ida Chen; Anton J M de Craen; Andre G Uitterlinden; Jerome I Rotter; Ian Ford; Albert Hofman; Naveed Sattar; P Eline Slagboom; Rudi G J Westendorp; Vilmundur Gudnason; Ramachandran S Vasan; Thomas Lumley; Steven R Cummings; Herman A Taylor; Wendy Post; J Wouter Jukema; Bruno H Stricker; Eric A Whitsel; Bruce M Psaty; Donna Arnett Journal: PLoS One Date: 2015-10-30 Impact factor: 3.240